

21 June 2004

ASX ANNOUNCEMENT

ASIC CLASS ORDER [02/1180] [ASX Code: PBT]

On 1 June 2004 Prana Biotechnology Ltd ("the Company") issued 40,000,000 ordinary shares (ASX Code: PBT) at US\$0.50 ("the Additional Securities"). The Additional Securities have been issued pursuant to the US Placement, issuing 1 American Depository Receipt (ADR) for every 10 ordinary fully paid shares held. The Company's ADRs are traded on the NASDAQ (NASDAQ Code: PRAN).

The Additional Securities are in classes that were quoted ED securities at all times in the 12 months before the date of issue. The Company has applied to the Australian Stock Exchange Limited ("the ASX") for quotation of the Additional Securities.


The Company gives notice pursuant to ASIC Class Order 02/1180 that there is no information to be disclosed which would be required to be disclosed under subsection 713(5) of the Corporations Act if a prospectus were to be issued in reliance on section 713 in relation to an offer of the securities (i.e. there is information that has been excluded from announcements to the ASX under the Listing Rules).

For and on behalf of
Prana Biotechnology Ltd

Richard Revelins
Company Secretary

About Prana's technology

PBT-1 and PBT-2 are Metal Protein Attenuating Compounds or MPACs. Prana's MPACs are chemicals that bind zinc and copper, and have been shown to lower the levels of amyloid beta (and associated toxicity) in the brains of transgenic mice used as a model of Alzheimer's Disease.



About Prana

Prana is a Melbourne-based biotechnology established in 1997 to commercialize research into Alzheimer's disease and other major age-related degenerative disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the company's researchers at prominent international institutions including Massachusetts General Hospital at Harvard Medical School, the University of Melbourne and the Mental Health Research Institute in Melbourne. For more information about Prana, please visit www.pranabio.com

For more information contact:

Company

Geoffrey Kempler, Prana
+61 (3) 9690 7892

Media and Investor, US

Ivette Almeida and Steven Silver
212-983-1702 ext. 209 and 212
ivette.almeida@annemcbride.com
silver@annemcbride.com

Media, Australia

Kate Mazoudier
+61 3 9866 4722
kmazoudier@bcg.com.au